BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

Stopped early · Phase 3

Conditions studied: Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

In brief

This randomized phase III trial studies 90-yttrium ibritumomab tiuxetan and combination chemotherapy compared with combination chemotherapy alone before stem cell transplant in treating patients with diffuse large b-cell non-Hodgkin lymphoma that has returned after a period of improvement. Radioactive substances linked to monoclonal antibodies, such as 90-yttrium ibritumomab tiuxetan, can bind to cancer cells and give off radiation which may help kill cancer cells. Drugs used in chemotherapy, such as carmustine, etoposide phosphate, cytarabine, and melphalan (BEAM), work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether 90-yttrium ibritumomab tiuxetan and BEAM before a stem cell transplant are more effective than BEAM alone in treating patients with diffuse large b-cell non-Hodgkin lymphoma.

Key facts

Study ID: NCT02366663
Run by: City of Hope Medical Center
People needed: 3
Starts: 2015-01-01
Expected to finish: 2016-10-01
Last updated by the study team: 2018-03-12

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with CD20 positive diffuse large B-cell lymphoma as confirmed by a pathological biopsy report.
Patients who are candidates for autologous stem-cell transplantation due to primary refractory or first relapse of disease.
Patients must have chemo-sensitive disease achieving at least partial response (Cheson 2007 criteria) to last chemotherapy.
Patients with adequate autologous stem cell collection for transplantation (target >= 2.5 x 10\^6 CD34+ cells/kg).
Patients must sign written informed consent.
Adequate birth control in fertile patients.
All prior chemotherapy completed at least three weeks before study treatment.
Marrow involvement less than 25% at transplantation, no limitation on blood counts (low platelet count allowed).
Negative HIV antibody.

You may not qualify if…

Chemo-refractory disease as determined by less than partial response (Cheson 2007 Criteria) to last chemotherapy.
Two or more relapses after initial response to induction chemotherapy.
High-grade transformation from earlier diagnosis of low-grade lymphoma. Patients with "De Novo" Transformed DLBCL, defined as DLBCL only on lymph node biopsy and a discordant marrow with para-trabecular small cells at first diagnosis of lymphoma, are eligible if adherent to all other selection criteria.
Bilirubin > 3.0 mg/dl, transaminases > 3 times upper normal limit.
Creatinine > 2.0 mg/dl.
KPS < 70.
Uncontrolled infection.
Pregnancy or lactation.
Abnormal lung diffusion capacity (DLCO < 40% predicted).
Severe cardiovascular disease; New York Heart Association (NYHA) Functional Classification ≥2.
Active CNS disease involvement.
Presence of any other malignancy or history of prior malignancy within 5 years of study entry. Within 5 years, patients treated for Stage I or II cancers are eligible provided they have a life expectancy > 5 years in relation to this prior malignance. The 5-year exclusion rule does not apply to-non melanoma skin tumors and in situ cervical cancer.
Pleural effusion or ascites > 1 liter.
Known hypersensitivity to rituximab.
Psychiatric conditions/disease that impair the ability to give informed consent or to adequately co-operate.
Prior radioimmunotherapy.
Prior autologous or allogeneic HSCT.
Active evidence of Hepatitis B or C infection; Hepatitis B surface antigen positive.
Patients who have had prior radiation to the lung will be excluded from the study, although mediastinal irradiation will be permitted if minimal lung is in the treatment volume.
Patients who have received >500cGy radiation to the kidneys will be excluded from the study.

Where it is running

City of Hope Medical Center — Duarte, California, United States
Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.